The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma

Çakar M. K., Tekgündüz E., Dal M. S., Merdin A., Başçı S., Uğur B., ...Daha Fazla

Journal of Oncology Pharmacy Practice, cilt.26, sa.2, ss.273-278, 2020 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1177/1078155219841110
  • Dergi Adı: Journal of Oncology Pharmacy Practice
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.273-278
  • Anahtar Kelimeler: Autologous hematopoietic stem cell transplantation, high-dose cytosine arabinoside, mantle cell lymphoma
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Introduction: The aim of this study was to investigate the influence of high-dose cytosine arabinoside (HDAC)-containing treatments followed by autologous hematopoietic stem cell transplantation on the survival of patients with mantle cell lymphoma. Material and methods: The data of 27 MCL patients who were followed-up between January 2009 and December 2015 were analyzed retrospectively. Results: The median age of the patients was 63 (range, 45–82) with 22 (81.4%) males and 5 (18.6%) females. Eight of 27 patients were treated with HDAC-containing regimens either as induction or salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT). The patients who received HDAC-containing regimen followed by AHSCT were found to have better one-year survival compared to others (p = 0.03). Median follow-up of patient cohort was 27.6 months and median overall survival (OS) was not reached. The probability of one-year OS for all patients was 76.8%. Conclusion: Our findings suggest that HDAC treatment followed by AHSCT seems to provide the best outcome for young-fit patients presenting with mantle cell lymphoma.